DR CONGO I URN: The Ebola Outbreak in Eastern DRC Raises Concern Over Strain Type, Delayed Detection, and Limited Vaccine Coverage. A suspected Ebola outbreak in the eastern Democratic Republic of Congo (DRC) is under investigation, with early reports indicating a growing number of cases and deaths in a remote, unstable mining region near international borders.
While confirmation is still pending, experts say early signals point to a possible Bundibugyo strain, though they caution that it is far too early to be certain.
“It seems like this outbreak might be the Bundibugyo strain and not Zaire… but it’s really hard to judge what might be going on because it’s still very early in the outbreak,” said Angela Lynn Rasmussen, an American virologist at the Vaccine and Infectious Disease Organization at the University of Saskatchewan in Canada.
Concerns are emerging that early warning signs may not have been acted on quickly enough, potentially delaying response efforts in a fast-moving outbreak.
“It seems that there were reports of suspected cases up to a week ago that were dismissed as rumors, and a delay of a week on something as consequential as Ebola is pretty significant,” she said.
Preliminary reports suggest around 250 suspected cases and approximately 65 deaths, though these figures remain unverified.
Experts caution that early outbreak numbers are often unstable and may reflect reporting delays or confirmation bias.
The outbreak is occurring in a remote mining area with ongoing instability, a combination that has historically complicated Ebola response efforts in the DRC.
“This is a fairly remote area. There’s a lot of mining, there’s also a lot of conflict in the area, and Ebola outbreaks in general in the DRC have really been hindered by security issues and violence,” added Lynn.
She warns that insecurity, population movement, and weak surveillance systems can allow outbreaks to spread before they are fully detected or contained.
There are also concerns that infected individuals may have moved toward larger towns or across borders. Ebola is not a single virus but a group of related viruses, including Zaire, Sudan, and Bundibugyo species, each with different outbreak patterns and historical mortality ranges.
“There’s a bunch of different species of Ebola viruses, but there’s not just one Ebola virus,” said Lynn. While Bundibugyo has historically been associated with lower mortality than Zaire, experts say early outbreak data can be misleading, especially when mild cases go undetected.
It’s really hard to judge what might be going on because the numbers we’re seeing so far… suggest that this actually might have a higher mortality rate than previous outbreaks,” she added. She said that it is still too early to make any conclusions.
“At the same time, though, it’s very early in the outbreak. It’s really too early to make that call.” Angela Lynn Rasmussen further explained. One of the most significant challenges is that available vaccines do not cover all Ebola species.
“The vaccine, however, is not cross-protective against these other species of Ebola virus,” she said.
“There is a phase two trial for Sudan virus vaccines. As far as I know, there is not a vaccine for Bundibugyo even in any kind of trial situation,” they added.
“That means there won’t be a vaccine that’s immediately available for use in controlling this.”
Experts warn this could severely limit outbreak control options, particularly in hard-to-reach or insecure areas where rapid vaccination campaigns are difficult to deploy.
Shealso addressed concerns circulating about whether Ebola could become airborne or spread like a respiratory virus.
“Ebola can be transmitted by the aerosol route, but it cannot be transmitted person to person,” she explained in reference to sustained transmission patterns. Transmission typically occurs through direct contact with bodily fluids, contaminated materials, or exposure during caregiving and burial practices.
“You do need to worry about the fact that in the past, the U.S. would have already had people from CDC responding to this outbreak… working with WHO,” one expert said, highlighting the importance of coordinated outbreak response. Once inside the body, Ebola primarily targets immune cells such as macrophages.
“Ebola virus has been transmitted experimentally to animals via the aerosol route… but once it gets into your lungs, the first cells it targets are macrophages,” one expert explained.
“These cells… basically go around gobbling up foreign material… but they are highly susceptible to the Ebola virus.”
The infection spreads rapidly as macrophages carry the virus into lymph nodes and the bloodstream.
“Once it’s there, uh-oh, there’s a whole bunch more macrophages… and they are all highly susceptible to Ebola virus.”
The result is a cascade of immune dysfunction. “They start dumping all of these pro-inflammatory cytokines into the bloodstream, which causes systemic inflammation.” This immune overreaction contributes to severe disease.
“It effectively makes your blood vessels leaky… which is necessary to make sure that you’re not bleeding out,” the expert said.
But in Ebola infection, that system breaks down. “It causes all kinds of problems with regulating vascular barrier function… and that is where one of the hallmark symptoms of Ebola virus disease occurs.”
As infection progresses, clotting systems become severely disrupted.
“It also causes your blood to clot abnormally… ” You end up with disseminated intravascular coagulation,” one expert explained.
“This is essentially blood that looks like coffee grounds.” The body’s clotting factors are consumed faster than they can be replaced. So that means your liver has to start making more of these clotting factors… but the hepatocytes are now starting to die.”
The result is a breakdown of normal blood clotting and widespread organ stress. “This is the mechanism by which Ebola causes hemorrhagic disease,” the expert said. Despite concerns, experts emphasize that Ebola is not adapted for respiratory spread between humans.
“When Ebola gets into your lungs… it does not get infected productively in respiratory epithelial cells,” one expert explained.
“That means… you’re not actually exhaling a ton of Ebola virus.”
While aerosol exposure can occur under specific conditions, sustained human-to-human airborne transmission is not seen.
“This is why it is probably not going to be airborne,” the expert concluded. Beyond the outbreak zone, experts warn that instability and limited response capacity could allow further spread before containment.
“This is really, really bad in terms of containment,” one expert said. Another warned that gaps in global response systems increase vulnerability.
“If this were a novel respiratory virus, we could potentially be in a pandemic by now without even knowing that the outbreak occurred,” she added: “The cuts to global health response capacity really say very, very worrisome things about what we would do if this happened elsewhere.”
Despite the concern, experts stress that Ebola does not currently pose a pandemic threat. “This is not something that has pandemic potential,” she emphasised.
“It is going to be very terrible for the people in the region who are affected… but Ebola requires very precise targeting for control measures.”
Health authorities continue to investigate as more laboratory confirmation and field data become available. For now, experts say the priority is rapid containment, improved surveillance, and access to protective interventions in a region where all.
